Valuation: Amgen Inc.

Market Cap 252B 225B 207B 188B 352B 23,837B 361B 2,465B 992B 12,581B 945B 924B 39,877B P/E 2026 *
29.5x
P/E 2027 * 26.3x
Enterprise Value 293B 262B 240B 218B 410B 27,755B 420B 2,870B 1,155B 14,649B 1,100B 1,076B 46,431B EV / Sales 2026 *
7.52x
EV / Sales 2027 * 7.1x
Free-Float
99.77%
Yield 2026 *
2.17%
Yield 2027 * 2.29%
1 day-1.44%
1 week+3.74%
Current month-1.02%
1 month+14.45%
3 months+19.76%
6 months+39.85%
Current year+40.92%
1 week 439.57
Extreme 439.57
475.64
1 month 396.01
Extreme 396.01
475.64
Current year 318.21
Extreme 318.21
475.64
1 year 294.48
Extreme 294.48
475.64
3 years 253.3
Extreme 253.3
475.64
5 years 198.64
Extreme 198.64
475.64
10 years 133.64
Extreme 133.64
475.64
Manager TitleAgeSince
Chief Executive Officer 63 30/04/2012
Director of Finance/CFO 62 12/05/2010
Chief Tech/Sci/R&D Officer 57 31/05/2023
Director TitleAgeSince
Chairman 63 31/12/2012
Director/Board Member 65 31/12/2011
Director/Board Member 71 31/12/2011
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Other

Chief Financial Officer

34,061 0.0063%
13/08/26 Exercice

Executive/Senior Manager

3,756 0.0007%
07/08/26 Free

Director

85 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%+3.74%+54.56%+73.02% 252B
-0.11%+10.18%+63.34%+142.88% 1,257B
-1.62%-0.05%+40.93%+77.16% 651B
-0.98%-0.26%+31.17%+99.64% 510B
-1.56%-1.39%+51.02%+64.18% 388B
-2.49%+2.89%+68.26%+40.66% 366B
-0.02%+3.15%+32.47%+55.33% 303B
-0.72%+7.05%+10.34%+32.79% 288B
-1.68%+5.53%+39.80%+106.17% 211B
-0.02%+3.72%-14.50%-61.92% 179B
Average -1.03%+4.51%+37.74%+62.99% 440.54B
Weighted average by Cap. -0.77%+5.24%+45.24%+85.44%

Financials

2026 *2027 *
Net sales 38.97B 34.82B 31.98B 29.05B 54.54B 3,692B 55.91B 382B 154B 1,948B 146B 143B 6,176B 40.4B 36.09B 33.15B 30.11B 56.54B 3,827B 57.96B 396B 159B 2,020B 152B 148B 6,402B
Net income 8.56B 7.65B 7.02B 6.38B 11.98B 811B 12.28B 83.84B 33.73B 428B 32.13B 31.44B 1,356B 9.44B 8.43B 7.75B 7.03B 13.21B 894B 13.54B 92.46B 37.19B 472B 35.43B 34.67B 1,496B
Net Debt 41.36B 36.95B 33.94B 30.82B 57.88B 3,918B 59.34B 405B 163B 2,068B 155B 152B 6,554B 35.3B 31.54B 28.97B 26.31B 49.41B 3,344B 50.65B 346B 139B 1,765B 133B 130B 5,595B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
03/11/26 US$461.26 -0.90% 2,355,692
02/11/26 US$465.45 -0.12% 3,196,517
30/10/26 US$466.01 +1.15% 3,290,626
29/10/26 US$460.73 +1.97% 2,982,878
28/10/26 US$451.83 +0.87% 2,912,150
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
465.45USD
Average target price
397.32USD
Spread / Average Target
-14.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.
  1. Stock Market
  2. Stocks
  3. AMGN Stock